Advanced Neurosciences Research, LLC

Summary

Advanced Neurosciences Research, LLC is a medical facility located in Fort Collins, Colorado. This center is recognized for care of Multiple Sclerosis, Migraine, Vestibular Migraine, Alzheimer's Disease, Wryneck and other specialties. Advanced Neurosciences Research, LLC is involved with conducting 39 clinical trials across 13 conditions. There are 0 research doctors associated with this hospital, such as .

Top PIs

Clinical Trials running at Advanced Neurosciences Research, LLC

Multiple Sclerosis

Migraine

Hyperacusis

Photophobia

Nausea and Vomiting

Vestibular Migraine

ABP 692 vs Ocrelizumab

for Multiple Sclerosis

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).

Recruiting

2 awards

Phase 3

1 criteria

Tolebrutinib

for Multiple Sclerosis

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy

Recruiting

1 award

Phase 3

Ocrelizumab Formulations

for Multiple Sclerosis

The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.

Recruiting

1 award

Phase 2

2 criteria